UARK 2014-08 A Phase II Open-Label, Multiple-Dose, Single Agent Study to Evaluate the Overall Response Rate of Orally Administered Trametinib

Summary

The purpose of this study is to evaluate the overall response rate of Trametinib when administered orally to patients with relapsed or refractory multiple myeloma

Timeline

Start

2015-03

Primary completion

2016-04

Completion

2016-04

Outcome

Outcome not reported

Stopped: “PI left institution”

Drugs

Indications